Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on
innovative oncology therapies, today announced that
chairman and CEO, will present at the 11th Annual BIO CEO & Investor
Conference 2009 on
Waldorf-Astoria in
Dr. McMahon will provide a corporate overview, including a discussion of
the clinical development program for picoplatin, the Company’s lead product
candidate.
A live audio webcast of the presentation will be available for 10 business
days on the “Events” page of the “News & Events” section of the Company’s
website at http://www.poniard.com.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc., is a biopharmaceutical company focused on
the development and commercialization of innovative oncology products to
impact the lives of people with cancer. Picoplatin, the Company’s lead
platform product candidate, is a new generation platinum chemotherapy. To
date, clinical studies suggest that picoplatin has an improved safety profile
relative to existing platinum-based cancer therapies. Picoplatin is designed
to overcome platinum resistance associated with chemotherapy in solid tumors,
and is being studied in multiple cancer indications, combinations and
formulations. Clinical trials of intravenous picoplatin include a Phase 3
trial in small cell lung cancer and Phase 2 trials in metastatic colorectal
and castration resistant prostate cancers (also known as hormone refractory
prostate cancer), as well as a clinical trial of oral picoplatin in solid
tumors. For additional information please visit http://www.poniard.com.
(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.
Poniard and Poniard Pharmaceuticals are trademarks of Poniard
Pharmaceuticals, Inc.
SOURCE Poniard Pharmaceuticals, Inc.